Clinical Trials

Phase 3 Clinical Trial of D-Fi for DEB

Date Updated:
EB Type: Dystrophic Epidermolysis Bullosa
Name of Company: Castle Creek Biosciences
Recruitment Status: Active, Not Recruiting

About the Study

The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Transportation, lodging, and a daily per diem for meals are provided; compensation for time may be provided.

Trial Entry Criteria

  • Male or female ≥2 years of age at the Screening visit
  • Clinical diagnosis of DEB with confirmation of COL7A1 genetic mutation.

Get more information on ClinicalTrials.gov

Contacts & Location

If you have questions regarding this clinical trial, or if you are interested in participating, please contact the study coordinator for the locations listed below:

  • Redwood City, CA
    • Location: Stanford University School of Medicine, M. Peter Marinkovich, MD
    • Study Coordinator: Kunju Sridhar
  • Santa Margarita, CA
    • Location: Mission Dermatology, Shireen Guide, MD
    • Study Coordinator: Kayla Kim 
  • Aurora, CO
  • Worcester, MA
    • Location: University of Massachusetts, Diana Reusch, MD
    • Study Coordinator: Priscilla Romano, Isaac Chen

Back to main Clinical Trials listing